Walmart Earnings Miss Due to Pharmaceutical Sales Decline

Walmart experienced its largest stock decline since 2022 following an earnings miss driven primarily by declining pharmaceutical sales, which have been impacted by new federal price negotiation policies. The company and investors anticipate this headwind will persist in the near term. To address concerns about slowing US sales growth, Walmart may need to leverage competitive pricing strategies to attract and retain customers.